Literature DB >> 5070123

The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs.

R Biggs, D E Austen, K W Denson, C R Rizza, R Borrett.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 5070123     DOI： 10.1111/j.1365-2141.1972.tb03467.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

2.  Studies on the altered electrophoretic type of the factor VIII related antigen.

Authors:  R Ananthakrishnan; S D'Souza; H Ekert
Journal:  Hum Genet       Date:  1976-12-29       Impact factor: 4.132

3.  Monoclonal antibodies against human factor VIII molecular neutralize antihemophilic factor and ristocetin cofactor activities.

Authors:  B Sola; P Avner; Y Sultan; C Jeanneau; P Maisonneuve
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

4.  [Current aspects on evaluation of assays of factor-VIII activity, factor-VIII associated protein and factor-VIII neutralizing antibody (author's transl)].

Authors:  G Hintz
Journal:  Blut       Date:  1978-02

Review 5.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

6.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

7.  Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.

Authors:  F Rossi; Y Sultan; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

8.  High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Authors:  Phuong-Cac T Nguyen; Kenneth B Lewis; Ruth A Ettinger; Jason T Schuman; Jasper C Lin; John F Healey; Shannon L Meeks; Pete Lollar; Kathleen P Pratt
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

9.  Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.

Authors:  Bhavya S Doshi; Bagirath Gangadharan; Christopher B Doering; Shannon L Meeks
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

10.  Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Authors:  Connie H Miller
Journal:  Haemophilia       Date:  2021-06-05       Impact factor: 4.263
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.